Fig. 4: PD-L1 IHC and sPD-L1 Analyses. | Nature Communications

Fig. 4: PD-L1 IHC and sPD-L1 Analyses.

From: Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

Fig. 4

The percentage of tumor cells (A) and immune cells (B) with PD-L1 expression at baseline, and the change in percentage of immune cells with PD-L1 expression after neoadjuvant treatment (C) were quantitated. The plasma concentration of soluble PD-L1 at baseline (D) and the change in sPD-L1 concentration (E) were measured. Tissue PD-L1 staining on tumor (F) and immune cells (G, H) was compared at baseline (F, G) and after neoadjuvant therapy (H). Data are separated by treatment cohort in Supplementary Figs. 2 and 3. Blue circles are ≤10% viable tumor. Red triangles are >10% viable tumors. A−E lines are medians.

Back to article page